title: Watch and wait approach to rectal cancer: A review.
abstract: In 2014, there were an estimated 136800 new cases of colorectal cancer, making it the most common gastrointestinal malignancy. It is the second leading cause of cancer death in both men and women in the United States and over one-third of newly diagnosed patients have stage III (node-positive) disease. For stage II and III colorectal cancer patients, the mainstay of curative therapy is neoadjuvant therapy, followed by radical surgical resection of the rectum. However, the consequences of a proctectomy, either by low anterior resection or abdominoperineal resection, can lead to very extensive comorbidities, such as the need for a permanent colostomy, fecal incontinence, sexual and urinary dysfunction, and even mortality. Recently, trends of complete regression of the rectal cancer after neoadjuvant chemoradiation therapy have been confirmed by clinical and radiographic evaluation-this is known as complete clinical response (cCR). The "watch and wait" approach was first proposed by Dr. Angelita Habr-Gama in Brazil in 2009. Those patients with cCR are followed with close surveillance physical examinations, endoscopy, and imaging. Here, we review management of rectal cancer, the development of the "watch and wait" approach and its outcomes.
authors.affiliation: Marcos E Pozo, Sandy H Fang, Ravitch Division, Colorectal Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, United States.
authors.forename: Marcos E
authors.initials: ME
authors.lastname: Pozo
authors.affiliation: Marcos E Pozo, Sandy H Fang, Ravitch Division, Colorectal Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, United States.
authors.forename: Sandy H
authors.initials: SH
authors.lastname: Fang
keywords: Neoadjuvant chemotherapy rectal cancer; Nonoperative management rectal cancer; Rectal cancer; Watch and wait approach